Correlation Between BRCA Mutation And Lymphatic Node Involvement In Advanced Stage Ovarian Cancer
DOI:
https://doi.org/10.25077/aoj.10.2.365-374.2026Keywords:
BRCA mutation, advanced stage ovarian cancer, lymphatic nodeAbstract
Background Gene mutations affecting the Breast Cancer-1 (BRCA1) and Breast Cancer-2 (BRCA2) genes are linked to ovarian and breast cancer which connected with a risk of ovarian cancer of 50% and 20%, respectively. High-grade serous ovarian cancer (HGSC) frequently has lymph node involvement. According to lymphatic drainage routes, the most prevalent site of nodal metastases is in the aortic area. A case of Cancer of Unknown Primary (CUP) with abdominal lymph node enlargement and high carbohydrate antigen 125 levels discovered a germline Breast Cancer 1 (BRCA1) p.L63* variant by a family history inquiry and BRCA analysis, indicating hereditary breast and ovarian cancer syndrome. Therefore we wanted to assess whether BRCA gene status correlates with lymph node involvement in advanced stage ovarian cancer.
Methods This was an analytic-observational study with cross sectional study design. The samples in this study were patients diagnosed with advanced stage ovarian cancer who were treated at M Djamil Padang General Hospital, Ibnu Sina Hospital Padang, and Ahmad Mochtar Hospital Bukittinggi by using data from BRCA somatic test results and anatomical pathology examination results. Data were being tested statistically with Chi-square/ Fischer test.
Result this study showed 1 patient (3,1%) with positive pathogenic mutation detected in BRCA1 gen with lymphatic node involvement, and 8 (25%) patients without lymphatic node involvement. This study also showed 3 patients (9,4%) with negative pathogenic mutation detected in BRCA1 gen with lymphatic node involvement, and 20 (62,5%) patients without lymphatic node involvement. There is no significant correlation between BRCA mutation and lymphatic node involvement in advanced stage ovarian cancer (p=1,0).
Conclusion BRCA mutation has no significant correlation with lymphatic node involvement in advanced stage ovarian cancer.
References
1. American College of Obstetricians and Gynecologists. Salpingectomy for ovarian cancer prevention committee opinion no 620. Obstetrics & Gynecology. 2015;125(1):279-281. doi:10.1097/01.AOG.0000459871.88564.09
2. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. Journal of the Turkish-German Gynecological Association. 2019;20(1):47-54. doi:10.4274/jtgga.galenos.2018.2018.0119
3. Gondhowiardjo S, Christina N, Ganapati NPD, et al. Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. JCO Glob Oncol. 2021;(7):190-203. doi:10.1200/GO.20.00155
4. Prihantono, Reski Rusli, Robert Christeven, Muhammad Faruk. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. Ethiop J Health Sci. 2023;33(3). doi:10.4314/ejhs.v33i3.15
5. Mulawardhana P, Hartono P, Nugroho H, Ayuningtyas A. Death of 43 Indonesian women with ovarian cancer: A case series. Int J Surg Case Rep. 2021;78:391-396. doi:10.1016/j.ijscr.2020.12.067
6. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402. doi:10.1001/jama.2017.7112
7. Toss A, Tomasello C, Razzaboni E, et al. Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes. Biomed Res Int. 2015;2015:1-11. doi:10.1155/2015/341723
8. Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. International Journal of Gynecologic Cancer. 2020;30(11):1803-1810. doi:10.1136/ijgc-2020-001556
9. Honar YS, Javaher S, Soleimani M, et al. Advanced stage, high-grade primary tumor ovarian cancer: a multi-omics dissection and biomarker prediction process. Sci Rep. 2023;13(1):17265. doi:10.1038/s41598-023-44246-9
10. Restaino S, Mauro J, Zermano S, et al. CUP-syndrome: Inguinal high grade serous ovarian carcinoma lymph node metastases with unknown primary origin – a case report and literature review. Front Oncol. 2022;12. doi:10.3389/fonc.2022.987169
11. Heublein S, Schulz H, Marmé F, et al. Extracapsular Lymph Node Involvement in Ovarian Carcinoma. Cancers (Basel). 2019;11(7):924. doi:10.3390/cancers11070924
12. Yamada J, Fukuda K, Sugawara T, et al. A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis. Int Cancer Conf J. 2024;13(2):139-143. doi:10.1007/s13691-023-00652-4
13. Gallotta V, Bruno M, Conte C, et al. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status. European Journal of Surgical Oncology. 2020;46(7):1327-1333. doi:10.1016/j.ejso.2020.01.035
14. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145-1153. doi:10.1055/a-1545-4279
15. Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm-Kähler P. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020;159(2):409-417. doi:10.1016/j.ygyno.2020.09.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ade Putra, Syamel Muhammad, Puja Agung Antonius
This work is licensed under a Creative Commons Attribution 4.0 International License.
